Literature DB >> 3492176

Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

J L Vildé, E Dournon, P Rajagopalan.   

Abstract

The activity of serial concentrations of different antimicrobial agents on the multiplication of Legionella pneumophila within human monocyte-derived macrophages was studied. The results led to the definition of a minimal extracellular concentration inhibiting intracellular multiplication (MIEC). According to the MIECs, the antimicrobial agents tested were classified in three groups: very active (MIEC less than or equal to 0.06 microgram/ml), such as erythromycin, rifampin, and pefloxacin; active (1 microgram/ml greater than or equal to MIEC greater than or equal to 0.1 microgram/ml), such as sulfamethoxazole-trimethoprim or doxycycline; and ineffective, such as cefoxitin, which was not active within macrophages at as high as 64 micrograms/ml despite a low MIC (0.2 microgram/ml) on bacterial charcoal-yeast extract agar. The activity of netilmicin was difficult to assess because of its effect on extracellular legionellae. Combinations of erythromycin with rifampin and pefloxacin with erythromycin, rifampin, doxycycline, or netilmicin showed an additive effect and no antagonism. These results obtained in a cellular model are in agreement with the efficacy of antimicrobial agents in experimental infections and in Legionnaires disease. They sustain clinical interest in the new quinolones, such as pefloxacin, and in combinations of antimicrobial agents for the treatment of Legionnaires disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492176      PMCID: PMC176525          DOI: 10.1128/AAC.30.5.743

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  In vivo susceptibility of the Legionnaires disease bacterium to ten antimicrobial agents.

Authors:  V J Lewis; W L Thacker; C C Shepard; J E McDade
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

3.  Pneumonia and multiple lung abscesses caused by dual infection with Legionella micdadei and Legionella pneumophila.

Authors:  J N Dowling; F J Kroboth; M Karpf; R B Yee; A W Pasculle
Journal:  Am Rev Respir Dis       Date:  1983-01

4.  Inactivation of beta-lactam antibiotics by Legionella pneumophila.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

5.  In vitro activity of antimicrobial agents on Legionnaires disease bacterium.

Authors:  C Thornsberry; C N Baker; L A Kirven
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

6.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

7.  Unresponsiveness of Legionella bozemanii pneumonia to erythromycin administration despite in vitro sensitivity.

Authors:  M M Parker; A M Macher; J H Shelhamer; J E Balow; V Gill; J E Parrillo
Journal:  Am Rev Respir Dis       Date:  1983-11

8.  Legionnaires' disease: description of an epidemic of pneumonia.

Authors:  D W Fraser; T R Tsai; W Orenstein; W E Parkin; H J Beecham; R G Sharrar; J Harris; G F Mallison; S M Martin; J E McDade; C C Shepard; P S Brachman
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

9.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

Review 10.  Legionella infections: a review of five years of research.

Authors:  R D Meyer
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  27 in total

1.  Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

Authors:  D M Johnson; M E Erwin; M S Barrett; B B Gooding; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Infection of macrophages with Legionella pneumophila induces phosphorylation of a 76-kilodalton protein.

Authors:  Y Yamamoto; T W Klein; H Shinomiya; M Nakano; H Friedman
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 4.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

5.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

7.  Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan; E Dournon; J L Vildé; J J Pocidalo
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

8.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; M A Franke; P B Michelsen
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.